Market Overview

UPDATE: Piper Jaffray Initiates Coronado Biosciences at Overweight on Compelling Clinical Results

Related CNDO
Coronado Biosciences Changes Its Name to Fortress Biotech
Morning Market Gainers

Piper Jaffray initiated coverage on Coronado Biosciences (NASDAQ: CNDO) with an Overweight rating and a $17.00 price target.

Piper Jaffray said, "We are initiating coverage of Coronado Biosciences with an Overweight rating and a $17 price target. We believe lead asset, CNDO-201, represents a novel approach to the treatment of autoimmune disease, using the porcine (pig) whipworm to modify the immune system and reduce inflammation. We believe early data suggests a highly differentiated profile and potential blockbuster status. … We see Phase IIb data from two ongoing Crohn's studies (2H13) as the key upcoming clinical catalysts, with Phase II trials from a range of multi-billion dollar indications (ulcerative colitis, MS, RA) providing further upside."

Coronado Biosciences closed at $7.31 on Thursday.

Latest Ratings for CNDO

Mar 2015MLV & Co.UpgradesHoldBuy
Nov 2013Bank of AmericaDowngradesNeutralUnderperform
Oct 2013MLV & Co.DowngradesBuyHold

View More Analyst Ratings for CNDO
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Initiation Analyst Ratings


Related Articles (CNDO)

View Comments and Join the Discussion!

Partner Center